Molecular Diagnostics is the fastest growing segment of the in vitro diagnostics market. The clinical application of molecular technologies to identify, diagnose, and monitor infectious, cancer and other diseases has made molecular diagnostics a powerful player in healthcare today. While technological advances in PCR (polymerase chain reaction), multiplexing and sequencing are supporting this rapid growth, restraints in healthcare spending is the major challenge this industry faces. It is imperative that new tests and systems are developed that can truly demonstrate clinical value and validity in order to achieve widespread adoption.

The Next Generation Dx Summit (Enabling Point-of-Care Diagnostics, Trends in Cancer Diagnostics, Clinical Adoption of Next Generation Diagnostics, and Molecular Diagnostics for Infectious Disease) is designed to bring together all of the major players in the Molecular Diagnostics arena. We have assembled an impressive faculty of speakers from the FDA, leading Medical Centers, Universities and Public Health Laboratories.  This meeting will showcase advances in technology, research and diagnostic development with special emphasis on clinical adoption and value.  Attend to gather competitive intelligence and learn what is critical to success in today’s market.